Boston, MA 02/10/2014 (wallstreetpr) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) the Cambridge, MA incorporated biopharmaceutical company is owner of one of the most successful leukaemia treating drugs in the world- Iclusig.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has in its latest press release noted that the company has now struck special marketing licenses with Australian marketing team- Specialised Therapeutics Australia Pty. Ltd. The new agreement will now allow the sale of Iclusig, which is Ponatinib in its chemical form to the patients suffering from Philadelphia –positive leukemia patients.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) will receive authorization of as well as pricing and reimbursement for the Iclusing.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Executive Vice President Marty J.Duvall expresses this model will prove to be the winner, to enter markets where they do not have a commercial team. The advantage with STA, was its long-term track record with the sale of oncology products as well as predominant access and entry to Australian markets.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has commented that Iclusig had received the marketing rights for the product in 2013, third quarter, in Australia. The Therapeutic Goods Administration (TGA) in Australia had approved the commercial launch by the fourth quarter of 2014. However, prior to its availability, the company will now offer refractory chronic myeloid leukemia as well as Philidalephia positive suffers to use Iclusig under special access program.
Importance of Iclusig
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s Iclusig is a critical therapy for such of the cancer patients as those who have failed to respond to such critical conditions as CML patients. The new line of treatment is expected to improve the refractory Australian patients and will deliver effective treatment options. Ausralian Institute of Health and Welfare has noted that the number of CML suffers in the country amounted to 1,500 patients. Of these nearly 290 patients are the most recently detected patients, under the year. Incidentally this is the number by which the patients who contract this condition have been 290.
